Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 23;14(1):62.
doi: 10.1186/s12985-017-0708-6.

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China

Affiliations

SVR Rates of HCV-infected population under PEG-IFN-α/R treatment in Northwest China

Yanhua Li et al. Virol J. .

Abstract

Background: Chronic HCV Patients taking PEG-IFN-α/R from different ethnic groups have different probabilities of reaching a sustained viral response (SVR). There are many influence factors, such as HCV genotype, IL-28B single-nucleotide polymorphisms (SNP), Fibrosis 4 index (FIB-4), and aspartate aminotransferase-to-platelet ratio index (APRI) score. But the baseline factors in relation to treatment outcome was still not much clear.

Methods: We evaluated data from 231 chronic HCV patients with or without liver fibrosis and their antiviral efficacy after treatment with pegylated interferon plus ribavirin (PEG-IFN-α/R) for 24-48 weeks. IL-28B SNP and HCV genotypes were analyzed with genome sequencing using pyrosequencing.

Results: Sustained viral response (SVR) rates of patients with HCV 1b and 2a genotypes were 52.25% (58/111) and 75.28% (67/89) (P < 0.01). SVR rates of patients with IL-28B rs8099917 TT, rs12979860 CC and rs12980275 AA were 92.41% (25/27), 92.86% (26/28) and 88.89% (24/27) separately. We found that SVR rates in HCV 1b and 2a patients were only 31.0 and 39.4% if their FIB-4 > 3.25. In addition, when their APRI > 2, only 30.3% of HCV 1b patients and 50.2% of HCV 2a patients could obtain SVR.

Conclusions: There were high proportion of HCV genotype 1b and 2a in Northwest China. In both HCV 1b and 2a genotypes, patients with protective-genotype of IL-28B were more likely to obtain SVR. However, those with significant fibrosis or cirrhosis were less likely, no matter their genotype. Combined factors of HCV genotype, IL-28B genotype, FIB-4 and ARPI may indicate high prediction and clinical value regarding treatment with PEG-IFN-α/R and prognostic evaluation of chronic hepatitis C patients.

Keywords: Chronic hepatitis C; Cirrhosis; HCV subtype; Individualization; Interleukin 28; Single nucleotide polymorphism.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of HCV genotype. 86% of the patients with HCV infection were genotype 1 and 2, with 1b accounting for 48.05% and 2a accounting for 38.53%, followed by 1a (5.19%), 3a (4.76%), 3b (2.16%), 2b (0.43%), and 6a (0.43%)
Fig. 2
Fig. 2
a Correlation between HCV genotype distribution and SVR. Sustained viral response (SVR) rates by HCV genotypes 1b and 2a were 52.25% (58/111) and 75.28% (67/89), statistically significant at P < 0.01. Rates of patients with HCV genotype 1b and 2a who did not reach SVR were 70.67 and 29.33%. Relationship between IL-28B genotype and SVR was showed in (b). SVR rates in patients of chronic HCV infection with different IL-28 single-nucleotide polymorphisms (SNP) (rs8099917 TT, rs12979860 CC and rs12980275 AA) were 92.41% (25/27), 92.86% (26/28), and 88.89% (24/27), respectively. In contrast, only 7.41, 7.14 and 11.11% of patients with IL-28B rs8099917 TG + GG, rs12979860 CT + TT, and rs12980275 AG + GG obtained SVR. c showed correlation among IL-28B SNP, HCV genotype and SVR

Similar articles

Cited by

References

    1. Antonelli A, Pistello M. New Therapies, Markers and Therapeutic Targets in HCV Chronic Infection, and HCV Extrahepatic Manifestations. Curr Drug Targets. 2015. - PubMed
    1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–57. doi: 10.1016/j.jhep.2014.07.027. - DOI - PubMed
    1. Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, et al. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol. 2012;12:162. doi: 10.1186/1471-230X-12-162. - DOI - PMC - PubMed
    1. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44. doi: 10.1056/NEJMoa1208953. - DOI - PubMed
    1. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–523. doi: 10.1016/S0140-6736(13)62121-2. - DOI - PubMed

MeSH terms

LinkOut - more resources